palbociclib + bortezomib + dexamethasone

Combination regimen of palbociclib, bortezomib, and dexamethasone studied in relapsed/refractory multiple myeloma. Palbociclib is a selective small-molecule inhibitor of cyclin-dependent kinase 4 and 6 (CDK4/6), which causes cell cycle arrest in the G1 phase. Bortezomib is a small-molecule proteasome inhibitor that disrupts protein degradation, inducing apoptosis in cancer cells. Dexamethasone is a synthetic glucocorticoid with antitumor and anti-inflammatory properties that enhances the efficacy of antineoplastic regimens by promoting apoptosis. The combination is investigated to exploit cell cycle arrest (palbociclib), proteasome inhibition (bortezomib), and glucocorticoid-induced apoptosis (dexamethasone) in a synergistic fashion for multiple myeloma. In a phase 1/2 study, this sequential combination demonstrated manageable safety and antitumor activity in relapsed/refractory multiple myeloma[1][3][10].

Brand names

IbranceVelcadeDecadron

Other names

Palbociclib/Bortezomib/Dexamethasone triplet